Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histological validation of artificial intelligence-driven automatic plaque characterization in coronary OCT: a head-to-head comparison with clinicians.

Cardiology plus·2026
Same author

Pathology outcomes of PI-RADS category 4 lesions in the peripheral zone: impact of MRI signal features and lesion size.

Acta radiologica (Stockholm, Sweden : 1987)·2026
Same author

The Effect of Osteopathic Manipulative Treatment Adjunct on Stabilization Splint Treatment in Temporomandibular Joint Anterior Disc Displacement with Reduction Disorder: A Quantitative Analysis, Pilot Study.

Journal of clinical medicine·2025
Same author

Artificial Intelligence in Diagnostic Breast Ultrasound: A Comparative Analysis of Decision Support Among Radiologists With Various Levels of Expertise.

European journal of breast health·2025
Same author

Evaluation of Neoadjuvant Chemoradiotherapy Response in Rectal Cancer Using MR Images and Deep Learning Neural Networks.

Current medical imaging·2024
Same author

Evaluating complete response prediction rates in locally advanced rectal cancer with different radiomics segmentation approaches.

Pathology oncology research : POR·2024

Related Experiment Video

Updated: May 18, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Drug eluting stents: current status and new developments.

Gökhan Ertaş1, Heleen Van Beusekom

  • 1Department of Cardiology, Faculty of Medicine, Bezmialem Vakıf University, İstanbul-Turkey. drgokhanertas@yahoo.com.tr

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|September 20, 2012
PubMed
Summary

Drug-eluting stents effectively reduce restenosis but raise concerns about stent thrombosis. Current technologies advance drug and polymer characteristics to improve long-term reliability of these critical medical devices.

More Related Videos

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Related Experiment Videos

Last Updated: May 18, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
06:55

Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents

Published on: October 26, 2016

Area of Science:

  • Cardiovascular Medicine
  • Biomaterials Science
  • Interventional Cardiology

Background:

  • Drug-eluting stents (DES) have significantly improved outcomes by reducing in-stent restenosis.
  • Long-term safety concerns persist, primarily related to stent thrombosis, an adverse event linked to stent platform interactions.
  • Advancements in polymer coatings and drug formulations aim to mitigate these risks.

Purpose of the Study:

  • To review the current landscape of drug-eluting stent technologies.
  • To discuss recent innovations and developments in DES design and function.
  • To address the ongoing challenges and future directions in improving DES long-term reliability.

Main Methods:

  • Comprehensive literature review of recent studies on drug-eluting stents.
  • Analysis of technological advancements in stent platforms, polymers, and eluted drugs.
  • Synthesis of data regarding efficacy and safety profiles of current and emerging DES.

Main Results:

  • Current DES technologies demonstrate improved efficacy in preventing restenosis.
  • Ongoing research focuses on bioabsorbable polymers and novel drug-eluting strategies.
  • Mitigation of adverse reactions through material science and drug delivery optimization is a key trend.

Conclusions:

  • Drug-eluting stents remain a cornerstone in interventional cardiology for managing coronary artery disease.
  • Continued innovation in materials and drug delivery is crucial for enhancing long-term safety and addressing stent thrombosis.
  • Future DES aim for superior biocompatibility and sustained therapeutic effects.